Evidence map›Paper›PMID 41389174›Full record

ArticleInternational journal of hematology2026

Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

Kohjin Suzuki, Tomoiku Takaku, Naoki Watanabe, Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, Maho Ishikawa, Hitomi Nakayama, Eriko Sato, Takayuki Tabayashi and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kohjin SuzukiDepartment of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Tomoiku TakakuDepartment of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan. ttakaku@saitama-med.ac.jp.ORCID http://orcid.org/0000-0002-6493-6225
Naoki WatanabeDepartment of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Noriyoshi IriyamaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Eisaku IwanagaDepartment of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
Yuta KimuraDepartment of Hematology, Japan Community Health Care Organization Saitama Medical Center, Saitama, Japan.
Maho IshikawaDepartment of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Hitomi NakayamaDepartment of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Eriko SatoDepartment of Hematology, Juntendo University Nerima Hospital, Tokyo, Japan.
Takayuki TabayashiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Toru MitsumoriDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Tomonori NakazatoDepartment of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Michihide TokuhiraDepartment of Hematology, Japan Community Health Care Organization Saitama Medical Center, Saitama, Japan.
Hiroyuki FujitaDepartment of Hematology, Saiseikai Yokohama Nanbu Hospital, Kanagawa, Japan.
Miki AndoDepartment of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Yoshihiro HattaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Tatsuya KawaguchiDepartment of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European LeukemiaNet recommendations for the management of chronic myeloid leukemia (CML) consider achievement of major molecular response (MMR) within 12 months to be an optimal response (OR). However, no currently available tool can predict treatment response at diagnosis. This study aimed to develop a predictive scoring tool for OR and subsequent deep molecular response (DMR) using peripheral blood parameters at diagnosis. A retrospective analysis was conducted in 535 patients with CML from the CML Cooperative Study Group database. Patients were categorized into OR (MMR within 12 months; n = 355) and non-OR groups (MMR after 13 months; n = 180). Logistic regression analysis identified white blood cell count, platelet count, eosinophil percentage, and imatinib use as significant predictors of OR. These variables were used to construct a novel score. The score was significantly higher in the non-OR group and showed superior predictive accuracy for OR compared with existing prognostic scores. Furthermore, lower scores correlated with higher rates of DMR achievement. Notably, the score effectively predicted OR achievement among patients with low/intermediate ELTS risk treated with imatinib. This new scoring tool may facilitate individualized treatment selection in CML, guiding upfront tyrosine kinase inhibitor selection and advancing precision medicine.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveAdultAgedAged, 80 and overFemaleHumansImatinib MesylateMaleMiddle AgedPrognosisProtein Kinase InhibitorsRetrospective StudiesTreatment OutcomeImatinib MesylateProtein Kinase InhibitorsChronic myeloid leukemiaOptimal responseTreatment response prediction

Identifiers

PMID41389174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.